Efficacy of Phlai capsule and loratadine as treatment in allergic rhinitis patients

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171111002

Enrollment

Registered

2017-11-11

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of Phlai capsule in allergic rhinitis patient Total nasal symptom scores Ocular scores Peak nasal inspiration flow Visual analogue scale

Interventions

Patient in this group take loratadine 10 mg (1 tablet)&#44

placebo Phlai 2 capsule before bedtime&#44

duration 8 wk and patient have to record daily total nasal symptom score. Visit schedule at 2&#44

4&#44

8 wk.,Patient in this group take Phlai 8 mg (2 capsules) and placebo loratadine 1 tablet fore bedime&#44

8 wk.,Patient in this group take Phlai 4 mg (1 capsule)&#44

placebo Phlai 1 capsule&#44

placebo loratadine 1 tablet before bedtime&#44

duration 8 wk and patient have to record daily total nasal symptom score. Visit schedule at 2&#44

8 wk.

Active Comparator Drug,Experimental Drug,Experimental Drug

Loratadine,Phlai 8 mg(2 capsules),Phlai 4 mg (1 capsule)

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.age between 18-50 years old 2. Diagnose of allergic rhinitis (at least mild intermittent) 3. Daily Total nasal symptoms score 6-10 on 3 consecutive day 4. Skin test positive at least one from five aeroallergen (house dust mite, cockroach, cat hair, dog dander, Bermuda grass) 5. Do not use - Intradermal nasal steroid 2 week - Systemic corticosteroid 2 week - Antihistamine 1 week - Intranasal or systemic decongestant 3 day 6. No smoking 7. No alcohol use 8. No allergic history to herb

Exclusion criteria

Exclusion criteria: 1. Have chronic illness or underlying disease (heart is ease, renal disease ,liver disease) 2. During on immunotherapy for allergic rhinitis treatment 3.Asthmatic patient 4.Take antidepressant, sedative ,anxiolytics, opioids, neuroleptic drug 5. After intranasal surgery within 6 months 6. Nasal polyp, nasal septum deviation, acute or chronic rhinosinusitis 7. Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Total nasal symptom score 8 wk Sum of score	—

Secondary

Measure	Time frame
Quality of life 8 wk Sum of score,Peak nasal inspiration flow 8 wk Mean score,Visual analogue scale score 8 wk Mean	—

Countries

Thailand

Contacts

Public ContactOrapan Poachanukoon

Faculty of medicine, Thammasat University

Orapanpoachanukoon@gmail.com0636542951

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026